Why IMU is a multi multi bagger, page-26884

Still cringe at the title of this thread.

After quick successive psotive results in its Azer-cel and CF33 VAXINIA trial updates IMU hit highs of $0.15 - it had made a $0.039 52 week low just prior - this stock really has surprised me on its continued fall.

I am happily buying here off tired and impatient IMU investors, who I think have forgotten the significance of Precision's partnership with TG Therapeutics to develop azer-cel as a treatment for autoimmune diseases and other indications outside oncology - IMU having bought the rights therein for oncology of course.

https://www.ncbiotech.org/news/precision-biosciences-closes-second-deal-leading-car-t-candidate

If the non-oncology IP is recently valued at an upfront payment of USD $7.5 million in cash and the purchase of stock and $2.5 million stock purchase and up to potentially $288 million in down the road payments, I think the market cap of $350 million on IMU on all of its wider science getting a little on the lean side (just as its silly valuation of near $2 billion in 2021 was a bit ridiculous).

Happily buying here.

GLTA(remaining)H.